Skip to main content
    O

    Orchestra BioMed Holdings Inc. (OBIO)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $6.97
    -0.15 (-2.11%)

    Market Cap: $560.38M

    Last updated: Nov 17, 2026 at 4:15 PM ET

    Orchestra BioMed Holdings Inc. (OBIO) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Orchestra BioMed Holdings (OBIO) has a market cap of $560.38M and an enterprise value of $568.54M. Revenue grew 1007.38% over the last 12 months from the 12 months before. It kept -182.50% of revenue as net income over the last 12 months.

    Total Valuation

    Enterprise value is 1.46% above the market cap, as debt exceeds cash.

    Market Cap$560.38M
    Enterprise Value$568.54M
    Latest price (Nov 17, 2026)$6.97

    Key Dates

    The next earnings report is expected on Mar 10, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 10, 2027 (expected)
    Last Earnings DateNov 10, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 1.27% in the quarter ended Sep 30, 2026 and grew 31.06% a year over 2 years.

    Shares Outstanding64.62M
    Shares Change (YoY)+23.83%
    Shares Change (QoQ)+1.27%
    Share Count Growth (2Y CAGR)+31.06%

    Valuation Ratios

    Sales and book value multiples are 14.4x and 57.9x. Its year-end P/S ranged from 4.8x to 104.0x from 2022 to 2025.

    P/S Ratio14.4x
    P/B Ratio57.9x

    Valuation history and multiples

    Price Statistics

    The stock is up 76.90% over 52 weeks and trades 17.34% above its 50-day average.

    Beta (1Y)1.53
    52-Week Change+76.90%
    1-Month Change+23.36%
    3-Month Change+25.59%
    6-Month Change+74.25%
    5-Year Change-40.06%
    Total Return (1Y)+76.90%
    Total Return (3Y CAGR)+0.88%
    Total Return (5Y CAGR)-6.73%
    Return vs SPY (1Y)+53.22%
    Max Drawdown (1Y)-34.77%
    Max Drawdown (3Y)-78.00%
    Sharpe Ratio (1Y)0.79
    Correlation with SPY (1Y)0.33
    50-Day Average$5.94
    200-Day Average$4.66
    52-Week Range$3.46 to $7.45
    RSI (14 Days)65.9
    Average Volume (20 Days)542.48K

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 7.25x current liabilities, and total debt is 4.62x shareholder equity.

    Current Ratio7.25x
    Quick Ratio7.24x
    Debt / Equity4.62x

    Returns and Efficiency

    Return on invested capital is -96.95% over the last 12 months, against a 5-year average of -59.51%.

    Return on Equity (ROE)-731.83%
    Return on Assets (ROA)-52.86%
    Return on Invested Capital (ROIC)-96.95%
    Return on Capital Employed (ROCE)-57.35%
    ROA (5Y Average)-42.60%
    ROIC (5Y Average)-59.51%
    Asset Turnover0.29x
    Inventory Turnover0.58x
    Receivables Turnover583.29x
    Cash Conversion Cycle-14346 days

    Scores

    OBIO has an Altman Z-Score of -2.86, in the distress zone below 1.81, and a Piotroski F-Score of 6 of 9, in the average band of 3 to 7.

    Altman Z-Score-2.86
    Altman Z ZoneDistress
    Piotroski F-Score6 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue was $31.21M over the last 12 months.

    Revenue$31.21M
    Revenue Growth (YoY)+1007.38%
    Gross Profit$31.07M
    Operating Income-$60.97M
    Pretax Income-$57.20M
    Net Income-$56.95M
    EBITDA-$53.75M
    EBIT-$53.63M
    Reported EPS (TTM)-$0.75

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 7.22% of the $107.74M in total assets.

    Cash and Equivalents$27.76M
    Total Debt$35.92M
    Net Debt$8.16M
    Net Debt Per Share$0.13
    Working Capital$88.94M
    Shareholder Equity$7.78M
    Book Value Per Share$0.12
    Total Assets$107.74M
    Total Liabilities$88.99M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $869.00K of capital spending, operating cash flow left -$64.18M of free cash flow.

    Operating Cash Flow-$63.31M
    Capital Expenditures$869.00K
    Free Cash Flow-$64.18M
    FCF Per Share-$1.04
    Depreciation and Amortization$1.09M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -195.39%.

    Gross Margin99.56%
    Operating Margin-195.39%
    Pretax Margin-183.31%
    Net Margin-182.50%
    EBITDA Margin-172.24%
    EBIT Margin-171.86%
    FCF Margin-205.66%

    Growth

    Revenue grew 111.62% a year over 3 years.

    Revenue Growth (3Y CAGR)+111.62%
    Revenue Growth (5Y CAGR)+42.48%
    Book Value Per Share Growth (2Y CAGR)-14.35%
    Tangible Book Per Share Growth (2Y CAGR)-14.35%

    Revenue and profit by year

    Dividends and Yields

    OBIO does not pay a dividend. Its free cash flow yield is -14.25%.

    FCF Yield-14.25%
    Shareholder Yield0.00%

    Peer Position

    Against 3 similar companies, OBIO has the 2nd highest P/S.

    P/S Ratio14.4x vs 1.7x median
    ROIC-96.95% vs -11.69% median
    Revenue Growth (Trailing 4 Quarters, YoY)+1007.38% vs -100.00% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at -86.61% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)-86.61%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewFairly valued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About OBIO

    What is OBIO's market cap?

    Orchestra BioMed Holdings has a market cap of $560.38M. Its enterprise value, which adds debt and subtracts cash, is $568.54M.

    How many shares of OBIO are outstanding?

    Orchestra BioMed Holdings has 64.62M shares outstanding. The count is up 23.83% from a year earlier.

    Does OBIO pay a dividend?

    No. Orchestra BioMed Holdings does not pay a dividend.

    How much debt does OBIO have?

    Orchestra BioMed Holdings has $35.92M of total debt and $27.76M of cash and equivalents, a net debt position of $8.16M.